Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Innoviva Inc.
Headquarters: Burlingame, CA, United States of America
Website: http://www.inva.com
Year Founded: 1996
Status: Public
Industry Sector: HealthTechnology
CEO: Pavel Raifeld, CFA, MBA
Number Of Employees: 127
Enterprise Value: $1,325,743,450
PE Ratio: 82.46
Exchange/Ticker 1: NASDAQ:INVA
Exchange/Ticker 2: N/A
Latest Market Cap: $1,081,152,384
BioCentury | Aug 14, 2024
Management Tracks
Innoviva vet Ronsheim joins Xenon
Plus: Manatt hires three new partners and a new CEO at Lobe
BioCentury | Jul 2, 2024
Management Tracks
Patricia Drake to lead commercial at Innoviva’s specialty unit
Plus: Thomas Mehrling name CEO of Swiss biotech Release, and Tenaya CSO Hoey stepping down
BioCentury | Jun 7, 2024
Management Tracks
Boston Pharma names Margaret Koziel CMO
Plus: Phillip Dennis joins I-Mab as CMO, and an update from Exscientia
BioCentury | Aug 25, 2023
Management Tracks
John Orwin named chairman at Cargo
Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
BioCentury | May 24, 2023
Finance
May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M
Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | May 3, 2023
Data Byte
At least 18 PDUFA dates on FDA’s calendar for May
The decisions include Sarepta’s DMD candidate, which could become the first gene therapy to receive accelerated approval
BioCentury | May 2, 2023
Management Tracks
Azam named CEO at Inspirna
Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Apr 18, 2023
Deals
April 17 Quick Takes: J&J, Pipeline in deal for remyelination therapy for MS
Plus: FDA approves Gamida Cell’s omidubicel and updates from Vaxcyte, Otsuka, Lundbeck, Innoviva and more
BioCentury | Apr 7, 2023
Politics, Policy & Law
The IRA is coming into focus
Adverse consequences, opportunities — and possible legal challenges — becoming clearer
BioCentury | Mar 15, 2023
Finance
March 14 Quick Takes: Switch launches with $52M and conditional gene knockdown tech
Plus: Servier’s vorasidenib meets glioma endpoint and updates from Teitur, AlgoTx, GSK, Acesion, Sophia Genetics and more
Items per page:
1 - 10 of 37